Experimental therapies to support the failing lung.
Many conventional therapies are designed to treat acute lung injury. Although evidence exists that improved outcomes are a result of these therapies, mortality remains high in this population. Perhaps one of the key reasons why mortality remains high in the failing lung population is that current therapies do not "cure" the problem; current therapies are designed to support the lung, rather than fix the pulmonary problem. In this paper, a review of new and experimental therapies to support the failing lung are presented. Therapies such as prone positioning, nitric oxide, and mediator therapies are addressed. It is likely that newer therapies offer the most hope for improving the high mortality associated with acute lung injury.
Ahrens
T S
TS
Beattie
S
S
Nienhaus
T
T
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D003422:Critical Care; D006801:Humans; D009569:Nitric Oxide / Q000627:therapeutic use*; D009730:Nursing Assessment; D012128:Respiratory Distress Syndrome / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*
D000276:Adjuvants, Immunologic; D009569:Nitric Oxide